InflaRx (IFRX) Stock Forecast, Price Target & Predictions
IFRX Stock Forecast
InflaRx stock forecast is as follows: an average price target of $6.00 (represents a 167.86% upside from IFRX’s last price of $2.24) and a rating consensus of 'Strong Buy', based on 2 wall street analysts offering a 1-year stock forecast.
IFRX Price Target
The average price target for InflaRx (IFRX) is $6.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 167.86% upside from IFRX's last price of $2.24.
IFRX Analyst Ratings
According to 2 Wall Street analysts, InflaRx's rating consensus is 'Strong Buy'. The analyst rating breakdown for IFRX stock is 1 'Strong Buy' (50.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
InflaRx Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 06, 2023 | H.C. Wainwright | $6.00 | $2.92 | 105.48% | 167.86% |
The latest InflaRx stock forecast, released on Jan 06, 2023 by H.C. Wainwright company, set a price target of $6.00, which represents a 105.48% increase from the stock price at the time of the forecast ($2.92), and a 167.86% increase from IFRX last price ($2.24).
InflaRx Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $2.24 | $2.24 | $2.24 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of InflaRx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to InflaRx's last price of $2.24. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 06, 2023 | Raymond James | Strong Buy | Strong Buy | Hold |
| Apr 05, 2023 | Guggenheim | Buy | Upgrade |
InflaRx's last stock rating was published by Raymond James on Apr 06, 2023. The company gave IFRX a "Strong Buy" rating, the same as its previous rate.
InflaRx Financial Forecast
InflaRx Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $376.65K | $192.40K | $124.75K | $334.43K | $113.81K | $79.74K | $60.63K | $1.27M | $1.28M | $2.40M | $220.00K | $5.30M | $5.17M | $124.37K | $18.74K |
| High Forecast | $484.87K | $247.68K | $160.59K | $430.51K | $196.58K | $83.14K | $62.53K | $1.32M | $1.31M | $3.09M | $283.21K | $5.30M | $5.17M | $124.37K | $18.74K |
| Low Forecast | $197.57K | $100.92K | $65.44K | $175.42K | $31.04K | $76.35K | $58.73K | $1.23M | $1.22M | $1.26M | $115.40K | $5.30M | $5.17M | $124.37K | $18.74K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
InflaRx's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IFRX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
InflaRx EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-9.79M | $-14.55M | $-12.49M | $-6.68M | $-9.72M |
| Avg Forecast | $225.99K | $115.44K | $74.85K | $200.66K | $68.29K | $47.85K | $36.38K | $764.00K | $767.99K | $1.44M | $132.00K | $-13.14M | $3.10M | $74.62K | $-12.42M |
| High Forecast | $290.92K | $148.61K | $96.35K | $258.31K | $117.95K | $49.88K | $37.52K | $792.04K | $788.61K | $1.85M | $169.93K | $-10.52M | $3.10M | $74.62K | $-9.94M |
| Low Forecast | $118.54K | $60.55K | $39.26K | $105.25K | $18.62K | $45.81K | $35.24K | $735.96K | $731.91K | $755.08K | $69.24K | $-15.77M | $3.10M | $74.62K | $-14.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | -74.19% | 1.11% | -4.03% | -89.51% | 0.78% |
undefined analysts predict IFRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than InflaRx's previous annual EBITDA (undefined) of $NaN.
InflaRx Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-12.22M | $-13.27M | $-12.68M | $-6.86M | $-9.84M |
| Avg Forecast | $-14.83M | $-14.28M | $-13.99M | $-16.73M | $-13.82M | $-14.67M | $-11.61M | $-13.15M | $-10.78M | $-14.02M | $-15.84M | $-12.65M | $-12.99M | $-18.12M | $-10.99M |
| High Forecast | $-5.66M | $-5.45M | $-5.34M | $-6.39M | $-12.90M | $-5.60M | $-4.43M | $-5.02M | $-8.08M | $-5.35M | $-6.05M | $-10.12M | $-12.99M | $-18.12M | $-8.79M |
| Low Forecast | $-20.36M | $-19.61M | $-19.22M | $-22.98M | $-14.28M | $-20.15M | $-15.94M | $-18.07M | $-13.47M | $-19.26M | $-21.76M | $-15.18M | $-12.99M | $-18.12M | $-13.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.77% | 1.05% | 0.98% | 0.38% | 0.90% |
InflaRx's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IFRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
InflaRx SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $3.61M | $4.39M | $2.32M | $1.17M | $3.30M |
| Avg Forecast | $19.55M | $9.99M | $6.48M | $17.36M | $5.91M | $4.14M | $3.15M | $66.10M | $66.44M | $124.54M | $11.42M | $3.96M | $268.52M | $6.46M | $972.69K |
| High Forecast | $25.17M | $12.86M | $8.34M | $22.35M | $10.20M | $4.32M | $3.25M | $68.52M | $68.23M | $160.32M | $14.70M | $4.76M | $268.52M | $6.46M | $972.69K |
| Low Forecast | $10.26M | $5.24M | $3.40M | $9.11M | $1.61M | $3.96M | $3.05M | $63.67M | $63.32M | $65.33M | $5.99M | $3.17M | $268.52M | $6.46M | $972.69K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.32% | 1.11% | 0.01% | 0.18% | 3.39% |
InflaRx's average Quarter SG&A projection for Sep 23 is $124.54M, based on 1 Wall Street analysts, with a range of $65.33M to $160.32M. The forecast indicates a 3351.25% rise compared to IFRX last annual SG&A of $3.61M (Mar 23).
InflaRx EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Mar 22 | Dec 21 | Sep 20 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 1 | 2 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.27 | $-0.30 | $-0.30 | $-0.25 | $-0.38 |
| Avg Forecast | $-0.25 | $-0.24 | $-0.24 | $-0.28 | $-0.23 | $-0.25 | $-0.20 | $-0.22 | $-0.18 | $-0.24 | $-0.27 | $-0.32 | $-0.22 | $-0.31 | $-0.52 |
| High Forecast | $-0.10 | $-0.09 | $-0.09 | $-0.11 | $-0.22 | $-0.10 | $-0.08 | $-0.09 | $-0.14 | $-0.09 | $-0.10 | $-0.32 | $-0.22 | $-0.31 | $-0.52 |
| Low Forecast | $-0.35 | $-0.33 | $-0.33 | $-0.39 | $-0.24 | $-0.34 | $-0.27 | $-0.31 | $-0.23 | $-0.33 | $-0.37 | $-0.32 | $-0.22 | $-0.31 | $-0.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.93% | 1.36% | 0.81% | 0.73% |
According to undefined Wall Street analysts, InflaRx's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IFRX previous annual EPS of $NaN (undefined).
InflaRx Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| HOWL | Werewolf Therapeutics | $1.64 | $12.00 | 631.71% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.40 | $10.00 | 614.29% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| SLS | SELLAS Life Sciences Group | $0.88 | $2.80 | 218.18% | Buy |
| EYPT | EyePoint Pharmaceuticals | $8.02 | $22.00 | 174.31% | Buy |
| IFRX | InflaRx | $2.22 | $6.00 | 170.27% | Strong Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| STOK | Stoke Therapeutics | $12.10 | $26.50 | 119.01% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |
| FULC | Fulcrum Therapeutics | $4.54 | $3.25 | -28.41% | Buy |